US2010209903A1PendingUtilityA1
Method for measuring resistance of a patient HIV-2 to protease inhibitors
Est. expiryJun 21, 2019(expired)· nominal 20-yr term from priority
C12Q 1/703
71
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A search method in a biological sample containing an HIV-2 viral strain for possible resistance of said strain to treatment by an anti-protease agent, and nucleotide probes for the implementation thereof. According to methods known per se, the presence of at least one mutation at certain, specified, particular positions of the proteinic sequence of the protease of said viral strain from a biological sample taken from a patient contaminated by HIV-2 is searched. If said mutation is observed, the existence of a resistance to said anti-protease agent is assumed in the patient.
Claims
exact text as granted — not AI-modified1 . A method for testing, in a biological sample from a patient infected by HIV-2 containing at least one HIV-2 viral strain, the resistance of said HIV-2 viral strain to treatment with an antiprotease agent, comprising investigating the presence of a mutation at position 46 of the protein sequence of the protease of said viral strain, said mutation having previously been found to elicit said resistance, and if such a mutation is found, concluding that a viral strain resistant to said antiprotease agent is present in the patient in question.
2 . The method according to claim 1 , wherein:
a) the presence of a mutation at position 46 of the protein sequence of the protease of said viral strain in a biological sample taken from a patient infected with HIV-2 is investigated, b) a mutation found in a) which, after cloning in an HIV-2 virus, does not prevent the virus clone obtained from multiplying in culture in the presence of said antiprotease drug is selected, and c) if the mutation is selected at step b), it is concluded that resistance exists to the antiprotease drug referred to in b).
3 . The method according to claim 1 , wherein the presence of the mutation I46V, in the protein sequence of the protease to said viral strain is investigated and in which said resistance is concluded to exist if said mutation is present.
4 . The method according to claim 1 , wherein, to detect a mutation of the protein sequence of the protease, a corresponding mutation is sought in the nucleotide sequence of the gene of said protease.
5 . The method according to claim 4 , wherein said test is carried out using hybridization techniques.
6 . The method according to claim 4 , wherein said test is carried out using sequencing techniques.
7 . The method of claim 4 , wherein said mutation in the sequence of the gene corresponds to I46V.
8 . The method of claim 7 , wherein said mutation corresponds to a codon for position 46, which is GTA, instead of ATA.
9 . The method of claim 1 , said method further comprising investigating the presence of at least one additional mutation at one or more of positions 10, 45, 54, 64, 82, 84 and 90 of the protein sequence of the protease of said viral strain.
10 . The method of claim 9 , wherein the at least one additional mutation is selected from the following mutations: V10I, K45R, 154M, I64V, I82M, I84L, and L90M.
11 . The method of claim 9 , wherein, to detect the at least one additional mutation of the protein sequence of the protease, at least one corresponding mutation is sought in the nucleotide sequence of the gene of said protease.
12 . The method of claim 9 , wherein said additional mutation is at said position 10.
13 . The method of claim 9 , wherein said additional mutation is at said position 45.
14 . The method of claim 9 , wherein said additional mutation is at said position 82.
15 . The method of claim 9 , wherein said additional mutation is at said position 54.
16 . The method of claim 9 , wherein said additional mutation is at said position 64.
17 . The method of claim 9 , wherein said additional mutation is at said position 84.
18 . The method of claim 11 , wherein said additional mutation corresponds to a condon for position 45, which is AGA, instead of AAA.
19 . The method of claim 11 , wherein said additional mutation corresponds to a condon for position 54, which is ATG, instead of ATA.
20 . The method of claim 11 , wherein said additional mutation corresponds to a condon for position 64, which is GTA, instead of ATA.
21 . A nucleotide probe usable in the method according to claim 1 , comprising, as a minimum sequence, a sequence selected from the group consisting of:
a) AAA GTA GTA possibly supplemented by the nucleotide sequence of an adjacent region of the gene of said protease, on either side of the minimum sequence,
b) a nucleotide sequence equivalent to a sequence defined in (a), and
c) a sequence complementary to a sequence defined in (a) or in (b).Join the waitlist — get patent alerts
Track US2010209903A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.